2021
GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans
Luther JM, Ray J, Wei D, Koethe JR, Hannah L, DeMatteo A, Manning R, Terker AS, Peng D, Nian H, Yu C, Mashayekhi M, Gamboa J, Brown NJ. GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans. Hypertension 2021, 78: 1092-1102. PMID: 34455816, PMCID: PMC8429121, DOI: 10.1161/hypertensionaha.121.17659.Peer-Reviewed Original Research
2017
Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery
Shuey MM, Billings FT, Wei S, Milne GL, Nian H, Yu C, Brown NJ. Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PLOS ONE 2017, 12: e0175292. PMID: 28552948, PMCID: PMC5446112, DOI: 10.1371/journal.pone.0175292.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseCardiac surgery cohortSoluble epoxide hydrolaseCardiac surgeryKidney injurySurgery cohortAcute Kidney Injury Network criteriaIncidence of AKIPostoperative acute kidney injuryPercent of patientsGlomerular filtration rateBody mass indexAssociation of gainsRenal injuryCardiopulmonary bypassWhite patientsMass indexKidney diseaseFiltration ratePharmacological strategiesDiscovery cohortNetwork criteriaVariant carriersSEH activity